23andMe’s Decline: The Rise and Fall of DNA Testing
By Olivia Harry
The downfall of 23andMe, once a pioneer in the DNA-testing industry, represents a dramatic shift for a company that promised to empower individuals through access to their genetic information. Once the leading provider in personalised genomics, the company’s journey has been marred by controversies related to data privacy, market saturation, and ethical concerns. The way 23andMe are managing this dramatic decline in stock value and leveraging the DNA of millions sparks an interesting discussion surrounding how the sensitive nature of genetic data fits into an era of increasing data privacy concerns.
As concerning as the future of the company may seem to its staff, the company’s 15 million users may have more to fear. Anne Wojciski, now the only remaining founder of three, has made it known that selling 23andMe is not something that she has ruled out, meaning the sizable repository of customer data would become commodified and sold along with the company. In response to a reporter from The Atlantic, a spokesperson of the company has recently acknowledged that it would be impossible to guarantee the protection of customer data – as stated in their fine print: The company reserves the right to update its policies at any time.
Hearing this, it’s hard not to think cynically. It isn’t difficult to imagine the value that the genomes of millions of Americans may have to large industries and co-operations, particularly since this fairly new form of technology isn’t a domain that is well-protected by government law. For example, gaps in the US 2008 Genetic Information Non-discrimination Act would render it completely legal for insurers to use your genetic information to deny you a policy, having discovered that you possess a genetic marker that correlates with a serious health condition.
The value of 23andMe’s genetic catalogue has already been highlighted through its use in the cold case of the Golden State Killer in 2018. By accessing a free, consumer DNA database containing records from 23andMe, Californian police officials were able to find individuals who were the equivalent of third cousins to the killer. Additional information offered by 23andMe profiles, including data on physical characteristics – which are not supposed to be on forensic databases – allowed them to narrow their search to just one individual. The ethical concerns surrounding this type of profiling and its implications for the privacy rights of law-abiding citizens are still part of on-going debate within Congress.
It would become completely legal for insurers to use your genetic information to deny you a policy, having discovered that you possess a genetic marker that correlates with a serious health condition
Due to similar concerns, in 2020 the US military issued a statement advising their personnel against all consumer DNA tests. These wide-spread concerns surrounding privacy proved to be justified, as in 2023 23andMe broke headlines with reports of a data breach that had exposed the personal information of 6.9 million customers. By logging into user accounts through passwords obtained elsewhere, hackers were able to gather information including the customers’ birth years and geographical locations. This wasn’t limited only to the hacked user, but also included the information of any relatives who they were linked to through their family tree.
Naturally, 23andMe’s capital took a substantial blow, and in 2023, the company ended the fiscal year at a $312 million loss. However, revenue reports reveal that the company was already showing signs of struggle the previous year, suggesting there were other factors at play in the company’s downfall. The company’s business model is likely a key contributor, as a single use product doesn’t leave room for future profit. Additionally, around this time, competing companies such as Ancestry and FamilyTreeDNA had emerged, offering identical, cheaper alternatives.
To combat this issue and to provide a more long-term business strategy, Wojciski shifted her focus towards the company’s drug development team, which sought to use the DNA provided by customers to invest into therapeutics, drug development and discovery. However, the cost and difficulty of these processes, combined with the delay between research and the yielding of results meant that this was ultimately unprofitable. Soon after, 23andMe announced that they were closing their drug development team and focusing on manufacturing obesity drugs, but whether this will be what is needed to save the company isn’t clear. The success of this new strategy isn’t yet known, but the most recent reports, showing a net loss of $667 million, don’t seem promising.
As 23andMe grapples with these financial losses and the resurfacing investigations surrounding its data leak, the future of the company remains uncertain. What we know is that the company’s legacy as an innovator in consumer genetics is fading. Amongst a landscape of public distrust and competition, the company’s fragile business model and struggles with data privacy feel part of a cautionary tale. For customers and stakeholders alike, the company’s struggles raise a pivotal question: can the advantages of genetic innovation be fully realised without sacrificing individual privacy and trust?
Image: Mike Mozart via Flickr

